Actively Recruiting
Evaluating the Safety and Effectiveness of SG301 SC Injection for Systemic Lupus Erythematosus in a Randomized, Placebo-Controlled Study
Led by Hangzhou Sumgen Biotech Co., Ltd. · Updated on 2026-09-17
120
Participants Needed
40
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of SG301 SC Injection in people diagnosed with Systemic Lupus Erythematosus SLE. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to measure how well the treatment works based on the Systemic Lupus Erythematosus Responder Index -4 SRI-4 response rate. Secondary goals include assessing the safety, how the drug is processed in the body, and its immune effects. Participants will receive SG301 SC Injection or a placebo through a series of 16 subcutaneous injections. The dosing schedule starts with one injection per week for 8 weeks, followed by injections every two weeks for another 8 doses. Some participants may receive placebo injections mixed within the treatment regimen. The study is designed with parallel groups and includes careful monitoring of drug effects and immune responses. During the study, participants will be regularly evaluated for disease activity, side effects, and immune responses. The main measure of success is the proportion of participants achieving an improved SRI-4 score from baseline to week 25. Study visits will include clinical assessments and safety monitoring. The total participant involvement extends through the treatment period and follow-up until study completion, expected by the end of 2027.
CONDITIONS
Brief Title
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
Research Team
Y
Yue Song
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here